Caspofungin

Caspofungin

Form: Intravenous (IV) Injection

Strength: 50 mg, 70 mg (single-use vials)

Reference Brands: Cancidas (US & EU)

Category: Critical Care

Caspofungin is an echinocandin antifungal used for treating invasive fungal infections such as candidemia, intra-abdominal candidiasis, and invasive aspergillosis in patients unresponsive to other therapies. It is available as a lyophilized powder for IV injection in 50 mg and 70 mg strengths. In the US, Caspofungin is marketed under the brand Cancidas by Merck and also supplied by generic manufacturers like Fresenius, Accord, and Mylan. In the EU, Cancidas and equivalent generics are distributed by Sandoz and others. Pharma B2B platforms enable reliable, large-scale sourcing of Caspofungin for hospitals and intensive care settings treating high-risk fungal infections.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (IV)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.